Rx00081 - Decitabine


Name:
Decitabine
Rx ID:
Rx00081
Validation Level:
Phenomic Similarity:
0.576
Reference ID:
DB01262
Primary Indications:
French-American-British myelodysplastic syndrome; myelodysplastic syndromes; refractory anemia; refractory anemia with ringed sideroblasts; refractory anemia with excess blasts; refractory anemia with excess blasts in transformation; chronic myelomonocytic leukemia
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Acute leukemia; chronic myelogenous leukemia; sickle cell anemia; acute myeloid leukemia
Common Indications:
French-American-British myelodysplastic syndrome; myelodysplastic syndromes; refractory anemia; refractory anemia with ringed sideroblasts
Drug Interactions:
No annotated drug interactions in DrugBank.
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00081
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
French-American-British myelodysplastic syndrome acute myeloid leukemia 941 941 941 4287.911 0 0.0
refractory anemia with ringed sideroblasts myelodysplastic syndromes 214 323 1504 1777.456 0 0.0
myelodysplastic syndromes refractory anemia with ringed sideroblasts 214 1504 323 1777.456 0 0.0
chronic myelomonocytic leukemia chronic myelogenous leukemia 433 433 433 9318.531 0 0.0
refractory anemia myelodysplastic syndromes 866 68895 1504 33.722 0 0.0
refractory anemia with excess blasts in transformation myelodysplastic syndromes 169 254 1504 1785.009 0 0.0
refractory anemia with excess blasts myelodysplastic syndromes 169 254 1504 1785.009 0 0.0

Shared Genetic Architectures of Disease Pairs

Click row to show all

Disease A Disease B Adjusted P-Value Shared Gene IDs
MYELODYSPLASTIC SYNDROMES CHRONIC MYELOGENOUS LEUKEMIA 1.27e-88 ABCB1, ABL1, ARHGAP26, ASXL1, BCOR, BCORL1, CBL, CEBPA, CXCL12, CYP1A1, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DNMT3A, EPO, ERCC1, ERCC2, ETV6, EZH2, FAS, FLT3, GATA2, GSTA1, GSTM1, GSTP1, GSTT1, HLA-A, HLA-B, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-DRB4, IDH1, IDH2, IFNG, IL10, IL1A, IL1B, IL1R1, IL1RN, IL4, IL6, IRF8, JAK1, JAK2, JAK3, KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5A, KIR2DL5B, KIR2DP1, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, KIR3DP1, KIR3DS1, KIT, KRAS, LIG1, MDM2, MEFV, MLL, MPL, MTHFR, NAT2, NPM1, NQO1, NRAS, PML, PTPN11, RUNX1, SETBP1, SF3B1, SRSF2, STAT3, TET2, TGFB1, TLX1, TNF, TP53, TYK2, TYMS, U2AF1, VDR, VEGFA, WT1, XPA, XRCC1, XRCC3, XRCC5
REFRACTORY ANEMIA MYELODYSPLASTIC SYNDROMES 5.74e-09 ASXL1, DNMT3A, HLA-DQB1, JAK2, RUNX1, SF3B1, TGFB1, TMPRSS6, TNF
REFRACTORY ANEMIA WITH EXCESS BLASTS REFRACTORY ANEMIA 2.88e-08 ASXL1, DNMT3A, RUNX1, SF3B1

Chemical, Pharmacological and Biological Annotations


ATC Code:
No ATC code annotated in DrugBank
Categories:
Enzyme Inhibitors; Antimetabolites, Antineoplastic; Teratogens
ChEBI ID:
50131
PubChem ID:
451668
KEGG Drug ID:
D03665
SMILE:
NC1=NC(=O)N(C=N1)[C@H]1C[C@H](O)[C@@H](CO)O1
InChI:
1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
Classification:
Kingdom:
Organic Compounds
Superclass:
Organooxygen Compounds
Class:
Carbohydrates and Carbohydrate Conjugates
Subclass:
Glycosyl Compounds
Indication:
For treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, ref...
Click to show more...
Pharmacodynamics:
Decitabine is an analogue of the natural nucleoside 2’-deoxycytidine. It functions in the same way as 5-Azacytidine. The antineoplastic activity of this drug is dependent on its intracellular conversion to its 5'-triphosphate metabolite.
Description:
Decitabine is indicated for treatment of patients with myelodysplastic syndrome (MDS). It is a chemical analogue of cytidine, a nucleoside present in DNA and RNA. Cells in the presence of Decitabine incorporate it into DNA during replicatio...
Click to show more...
Mechanism:
Decitabine is believed to exert its antineoplastic effects following its conversion to decitabine triphosphate, where the drug directly incorporates into DNA and inhibits DNA methyltransferase, the enzyme that is responsible for methylating...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
-
P-glycoprotein substrate:
Non-substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
1.9436 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org